sstr

Octreotide (SMS 201-995) is a potent inhibitor of growth hormone, glucagon, and insulin.

Pasireotide (SOM230) acetate is a long-acting cyclohexapeptide growth hormone inhibitory hormone analog with antisecretory, antiproliferative, and proapoptotic activities.Pasireotide (SOM230) acetate inhibits the secretion of GH, IGF-I, and ACTH, and can be used in the study of acromegaly and Cushing's disease. Pasireotide (SOM230) acetate also enhances the agonist activity of growth inhibitory receptors, with pKi of 8.2, 9.0, 9.1, <7.0 and 9.9 for sst1, 2, 3, 4 and 5, respectively.

Octreotide Acetate (Sandostatin) is a potent, long-acting synthetic somatostatin octapeptide analog that inhibits secretion of growth hormone.

Octreotide, a cyclic SSTR agonist, serves as the cyclic Somatostatin Receptor SSTR agonist [1].

Potent somatostatin receptor 1 (sst1) agonist; displays selectivity for sst1 (IC50 values are 30.9 nM, 345 nM, > 1 μM, > 10 μM and > 10μM for human sst1, sst3, sst4, sst2 and sst5 respectively). Attenuates somatostatin release in the rat nucleus accumbens

NODAGA-LM3 TFA, a SSTR2 antagonist, can be radiolabeled with ^68Ga for PET imaging applications, particularly in the visualization of SSTR-positive paragangliomas [1] [2].

DOTA-LM3 is a somatostatin receptor (SSTR) antagonist, with LM3 denoting the peptide sequence p-Cl-Phe-cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH2. It is utilized in the isotopic labeling of tumors for in vivo tracing, notably with 177Lu-DOTA-LM3 and 68Ga-DOTA-LM3. The derivative 68Ga-DOTA-LM3 exhibits promising biodistribution, high tumor uptake, efficient tumor retention, and minimal safety concerns, while 177Lu-DOTA-LM3 is applied in research on DOTATOC-negative liver metastases including pancreatic NET and extensive tumor thrombosis [1] [2].

NODAGA-LM3, when labeled with ^68Ga, serves as a PET imaging agent. As an SSTR2 antagonist, ^68Ga-NODAGA-LM3 is utilized for the visualization of SSTR-positive paragangliomas [1] [2].